Kinase Inhibitor Discovery
with an untiring quest for future therapeutics

FY2025 Q3 Presentation

Consolidated Financial Results for the Third Quarter of the Year Ending December 31, 2025

Carna announces acceptance of two posters on docirbrutinib for presentation at the 67th ASH Annual Meeting

FY2025 Q2 Presentation

Consolidated Financial Results for the Second Quarter of the Year Ending December 31, 2025

Docirbrutinib, a next generation BTK inhibitor, demonstrates promising and durable responses in patients with B-cell malignancies in Phase 1b study

Carna Announces Upcoming Poster Presentation of Preliminary Results from Ongoing Phase 1b Study of Docirbrutinib, a Non-covalent Pan-mutant BTK Inhibitor, at the European Hematology Association Congress (EHA) 2025

FY2025 Q1 Presentation